What is it about?
Peroxisome proliferator-activated receptor delta (PPARδ) is an important protein involved in regulating metabolism, energy balance, and inflammation. Because of this, it is a promising target for developing drugs to treat conditions such as metabolic disorders and cardiovascular diseases. In this study, we developed a read-across model to predict the biological potency of new compounds that activate PPARδ. Read-across works by comparing new molecules to similar known compounds and estimating their activity based on structural similarity. We created a robust dataset of known PPARδ agonists and used advanced cheminformatics techniques to analyze their chemical features. The model groups compounds into similarity categories and predicts how strongly they interact with the receptor. Importantly, the model follows internationally accepted guidelines for predictive modeling, ensuring that its predictions are reliable and scientifically valid. It can be used to estimate the potency of new compounds without the need for immediate laboratory testing.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Developing new drugs is a long and expensive process, and early-stage screening of candidate molecules is a major bottleneck. This work is important because it provides a fast, cost-effective, and reliable method to predict drug activity, helping researchers prioritize the most promising compounds for further development. By using read-across instead of experimental testing, the approach reduces time, cost, and reliance on laboratory experiments. It also supports safer drug development by identifying potentially effective compounds earlier in the process. Additionally, the model enhances understanding of how chemical structure influences biological activity, which is essential for rational drug design.
Perspectives
This study highlights the growing role of data-driven approaches in modern drug discovery. Read-across methods offer a balance between simplicity, interpretability, and predictive power, making them particularly valuable for regulatory and industrial applications. From a personal perspective, a key contribution is the development of a transparent and robust framework that aligns with regulatory expectations, increasing confidence in computational predictions. Looking ahead, combining read-across with machine learning and molecular modeling could further improve predictive accuracy and expand applicability to other biological targets. Such approaches will play an increasingly important role in accelerating drug discovery, reducing costs, and enabling more efficient development of therapies for complex diseases.
Dr Antreas Afantitis
NovaMechanics Ltd
Read the Original
This page is a summary of: Development of a Robust Read-Across Model for the Prediction of Biological Potency of Novel Peroxisome Proliferator-Activated Receptor Delta Agonists, International Journal of Molecular Sciences, May 2024, MDPI AG,
DOI: 10.3390/ijms25105216.
You can read the full text:
Contributors
The following have contributed to this page
